Analysis Tools
mortality/aging
|
• following treatment with a high dose of DSS, survival is decreased by day 4 and drops to 50% by day 5 whereas similarly treated wild-type mice do not exhibit any decrease in survival
(J:60668)
• mice treated with azoxymethane and dextran sulfate sodium exhibit increased mortality compared with similarly treated wild-type mice
(J:158426)
|
|
• about 20% of mice die between 7 and 23 weeks of age
|
immune system
|
• mice treated with a high dose of DSS exhibit increased weight loss, intestinal inflammation score, and mortality compared with similarly treated wild-type mice
(J:60668)
• DSS-treated mice fail to exhibit an increase in colonic secretion of prostaglandin unlike similarly treated wild-type mice
(J:60668)
• mice treated with a low dose of DSS exhibit increased clinical inflammation and weight lose compared with similarly treated wild-type mice
(J:60668)
• DSS-treated mice exhibit increased colonic shortening, colonic weight to length ratio, splenomegaly, white blood cell counts, and crypt damage and decreased hematocrit compared with similarly treated wild-type mice
(J:60668)
• DSS-treated mice exhibit a more aggressive mucosal injury than in similarly treated wild-type mice and Ptgs1tm1Unc homozygotes
(J:60668)
• mice treated with azoxymethane and dextran sulfate sodium exhibit increased mortality compared with similarly treated wild-type mice
(J:158426)
|
|
• in 2 of 10 mice unlike wild-type mice
|
|
• in DSS-treated mice compared with similarly treated wild-type mice
|
|
• in DSS-treated mice compared with similarly treated wild-type mice
|
|
• in the pancreas and bronchoalveolar lavage fluid of cerulein-treated mice compared with similarly treated wild-type mice
|
|
• LPS-treated mice exhibit less weight loss than similarly treated wild-type mice
|
digestive/alimentary system
|
• DSS-treated mice exhibit increased colonic shortening and colonic weight to length ratio compared with similarly treated wild-type mice
|
|
• mice treated with a high dose of DSS exhibit increased weight loss, intestinal inflammation score, and mortality compared with similarly treated wild-type mice
(J:60668)
• DSS-treated mice fail to exhibit an increase in colonic secretion of prostaglandin unlike similarly treated wild-type mice
(J:60668)
• mice treated with a low dose of DSS exhibit increased clinical inflammation and weight lose compared with similarly treated wild-type mice
(J:60668)
• DSS-treated mice exhibit increased colonic shortening, colonic weight to length ratio, splenomegaly, white blood cell counts, and crypt damage and decreased hematocrit compared with similarly treated wild-type mice
(J:60668)
• DSS-treated mice exhibit a more aggressive mucosal injury than in similarly treated wild-type mice and Ptgs1tm1Unc homozygotes
(J:60668)
• mice treated with azoxymethane and dextran sulfate sodium exhibit increased mortality compared with similarly treated wild-type mice
(J:158426)
|
|
• in 2 of 10 mice unlike wild-type mice
|
growth/size/body
| N |
• mice display normal somatic growth from birth to 42 days of age
|
|
• at birth, mice exhibit a significantly higher heart weight:body weight ratio relative to control mice
• however, a normal ratio is observed during postnatal growth and early adulthood
|
weight loss
(
J:60668
)
|
• compared with wild-type mice when treated with a high or low dose of DSS
|
kidney cyst
(
J:104002
)
|
• early cystic changes affecting different tubule sections and glomeruli at P10, with slightly variable pathologic progression
• severe cyst formation by P28
|
|
• massive tubular cysts in severely affected kidneys at P14
|
|
• by P14, all mice exhibit cystic subcapsular glomeruli
|
|
• in DSS-treated mice compared with similarly treated wild-type mice
|
homeostasis/metabolism
| N |
• adult mice exhibit normal plasma sodium, potassium, bicarbonate and chloride levels relative to wild-type controls
|
|
• following ischemia, maximum contracture is higher and recovery of contractile function is lower than in similarly treated wild-type mice
• however, pre-conditioned mice exhibit normal recovery from myocardial ischemia
|
|
• adult mice exhibit a 1.5-fold increase in plasma creatinine levels relative to controls
|
|
• adult mice exhibit a 2.5-fold increase in plasma BUN levels relative to controls
|
|
• cerulein-treated mice exhibit reduced pancreatic and lung myeloperoxidase levels compared with similarly treated wild-type mice
|
|
• in the bronchoalvealor lavage fluid of cerulein-treated mice compared with similarly treated wild-type mice
|
|
• DSS-treated mice fail to exhibit an increase in colonic secretion of prostaglandin unlike similarly treated wild-type mice
(J:60668)
• in keratinocyte cultures
(J:117986)
|
|
• following treatment with a high dose of DSS, survival is decreased by day 4 and drops to 50% by day 5 whereas similarly treated wild-type mice do not exhibit any decrease in survival
(J:60668)
• mice treated with azoxymethane and dextran sulfate sodium exhibit increased mortality compared with similarly treated wild-type mice
(J:158426)
|
|
• mice treated with azoxymethane alone fail to develop colon tumors unlike similarly treated wild-type mice
|
|
• cerulein-treated mice exhibit less pancreatitis-associated lung injury compared with similarly treated wild-type mice
|
hematopoietic system
|
• in DSS-treated mice compared with similarly treated wild-type mice
|
|
• DSS-treated mice exhibit reduced hematocrit compared with similarly treated wild-type mice
|
|
• DSS-treated mice exhibit reduced hematocrit compared with similarly treated wild-type mice
|
|
• in DSS-treated mice compared with similarly treated wild-type mice
|
cardiovascular system
| N |
• normal systolic blood pressure in awake or anesthetized mice relative to wild-type controls
|
|
• at birth, mice exhibit a significantly higher heart weight:body weight ratio relative to control mice
• however, a normal ratio is observed during postnatal growth and early adulthood
|
|
• following ischemia, maximum contracture is higher and recovery of contractile function is lower than in similarly treated wild-type mice
• however, pre-conditioned mice exhibit normal recovery from myocardial ischemia
|
muscle
| N |
• mice exhibit normal internal anal sphincter muscle tone
|
endocrine/exocrine glands
|
• in cerulein-treated mice compared with similarly treated wild-type mice
|
|
• following supramaximally stimulating doses of cerulein, mice develop decreased pancreatitis and associated lung injury with reduced , acinar cell necrosis, pancreatic and lung myeloperoxidase activity, bronchoalveolar lavage (BAL) fluid lactate dehydrogenase levels, and pancreatic and BAL TNF-alpha levels compared with similarly treated wild-type mice
|
neoplasm
|
• mice treated with azoxymethane alone fail to develop colon tumors unlike similarly treated wild-type mice
|
|
• mice treated with azoxymethane and dextran sulfate sodium exhibit more colon tumors than similarly treated wild-type mice
• however, the histology of induced-tumors is the same as in similarly treated wild-type mice
|
integument
|
• keratinocyte cultures exhibit a 5-fold increase in expression of K1, a marker of differentiation, compared with wild-type cells
|
cellular
|
• keratinocyte cultures exhibit a 5-fold increase in expression of K1, a marker of differentiation, compared with wild-type cells
|
renal/urinary system
| N |
• adult mice exhibit normal urinalysis and 24-hr urine output under non-stressed conditions
• no significant differences in urine osmolarity or in daily urinary excretion of sodium, potassium and chloride are observed
|
kidney cyst
(
J:104002
)
|
• early cystic changes affecting different tubule sections and glomeruli at P10, with slightly variable pathologic progression
• severe cyst formation by P28
|
|
• massive tubular cysts in severely affected kidneys at P14
|
|
• by P14, all mice exhibit cystic subcapsular glomeruli
|
|
• by P14, all mice exhibit outer cortical dysplasia
• inner cortical nephron hypertrophy by P42
|
|
• small, crowded glomeruli in subcapsular region at P10
• outer cortical glomerular hypoplasia at P42
|
|
• focally variable glomerular sclerosis by P42
• however, no inflammatory infiltrate or vascular pathology is observed at any stage
|
|
• peri-glomerular fibrosis by P42
|
|
• hypertrophy of juxtamedullary glomeruli at P28
• inner cortical glomerular hypertrophy by P42
|
|
• mice exhibit progressive cystic dysplasia during the later stages of kidney development
• however, prenatal and early postnatal kidney development appears normal
|
|
• diffuse interstitial fibrosis by P42
|
|
• starting at P10, total kidney mass is significantly reduced relative to that in wild-type controls
• kidney-specific growth suppression persists to P42 with no significant change
|
|
• by P14, all mice exhibit loss of proximal tubular mass
|
|
• variable loss of normal proximal tubule mantle at P10
|
|
• by P14, all mice exhibit loss of brush border definition
|
|
• variable tubular dilation at P10
• severe diffuse tubular dilation by P42
|
|
• hypertrophy of juxtamedullary tubules by P28
|
|
• at 8 weeks of age, some mice exhibit more severe cystic degeneration than others
|
|
• adult mice exhibit a ~50% reduction in GFR relative to wild-type controls, as measured by inulin clearance
|
|
• mice exhibit progressive renal insufficiency
|
behavior/neurological
| N |
• mice exhibit normal daily water intake under non-stressed conditions
|
